Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN Novo Nordisk advances obesity candidate to late stage program after weight loss of less than 12% Novo Next Generation Obesity Shot Falls Short of Lilly Rival Bloomberg Cagrilintide Research Peptide Information Peptpedia Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect Novo Nordisk: A long acting, selective human insulin analog, NN1213, for weight management